

## CefTRIAxone

<b>SALAD</b> <b>Contains a PENICILLIN-like structure</b> May be appropriate in penicillin-allergic patient. Refer to CUH Antimicrobial Guidelines on Eolas for further information before administration													
<b>Form</b>	1g dry powder vial												
<b>Reconstitution</b>	<u>IV Administration:</u> Add 10mL WFI to 1g vial.  <u>IM Administration</u> add 3.5mL Lidocaine 1% to 1g vial.												
<b>Compatibility &amp; Stability</b>	Sodium Chloride 0.9% Glucose 5% <b>Incompatible with</b> calcium-containing solutions. See Additional Information.  <b><u>From a microbiological point of view, should be used immediately;</u></b> however: <ul style="list-style-type: none"> <li>• Reconstituted vials may be stored at 2–8°C for 24 hours. Protect from light.</li> <li>• Prepared infusions may be stored at 2–8°C and infused (at room temperature) within 24 hours. Protect from light.</li> </ul>												
<b>Administration</b>	The reconstituted solution should be clear. Do not use if particles are present. <b><u>IV Injection:</u></b> Slow IV injection 5 minutes preferably via a large vein.  <b><u>IV Infusion: Preferred</u></b> <b>Step 1:</b> Reconstitute dry powder vial as per guidance above <b>Step 2:</b> Discard Volume from 50mL infusion bag as per table below <b>Step 3:</b> Add reconstituted dose to infusion bag to achieve a final concentration of 50mg/mL.  Administer over at least 30 minutes. <table border="1" style="margin: 10px auto; width: 80%; border-collapse: collapse;"> <thead> <tr> <th style="background-color: #e0f2f7;">Volume discarded from 50mL bag</th> <th style="background-color: #e0f2f7;">Volume left in 50mL bag</th> <th style="background-color: #e0f2f7;">Dose to be added</th> <th style="background-color: #e0f2f7;">Final Volume for infusion</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">40mls</td> <td style="text-align: center;">10mL</td> <td style="text-align: center;"><b>1g</b> (in 10mL WFI)</td> <td style="text-align: center;">20mL</td> </tr> <tr> <td style="text-align: center;">30mls</td> <td style="text-align: center;">20mL</td> <td style="text-align: center;"><b>2g</b> (in 20mL WFI)</td> <td style="text-align: center;">40mL</td> </tr> </tbody> </table> <b><u>IM Injection:</u></b> Withdraw the required dose. For intramuscular injection, doses over 1g must be divided between more than one site.	Volume discarded from 50mL bag	Volume left in 50mL bag	Dose to be added	Final Volume for infusion	40mls	10mL	<b>1g</b> (in 10mL WFI)	20mL	30mls	20mL	<b>2g</b> (in 20mL WFI)	40mL
Volume discarded from 50mL bag	Volume left in 50mL bag	Dose to be added	Final Volume for infusion										
40mls	10mL	<b>1g</b> (in 10mL WFI)	20mL										
30mls	20mL	<b>2g</b> (in 20mL WFI)	40mL										
<b>Additional Information</b>	<ul style="list-style-type: none"> <li>• CefTRIAxone and calcium-containing solutions (compound sodium lactate (Hartmann's solution), Ringer's solution and total parenteral nutrition) must not be mixed or administered <b>simultaneously</b>, even via different infusion lines, because of the risk of precipitation.</li> <li>• CefTRIAxone and calcium-containing solutions may be administered <b>sequentially</b>, one after the other, if infusion lines at different sites</li> </ul>												

*This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542*

are used or if the infusion line is flushed or replaced between infusions.

- Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—risk of dizziness.

**Information provided relates to Rocephin manufactured by Roche, CefTRIAxone manufactured by Pinewood and Kalceks, and Medaxonum(unlicensed medicine) manufactured by Medochemie Ltd.**